In addition, c-MET in cancer cells is highly sensitive to antibody-induced internalisation, and the high efficiency of cytotoxic payloads to kill tumour cells requires antibody internalisation; therefore, c-MET therapy has inherent potential as a clinical anti-cancer option (25, 26). Here, MET is linked to neoplasm.